Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

morning brief

- PMLiVE

Building brand strength – Part 4

Commitment, responsiveness and protection – how far will Big Pharma go to preserve its brands?

- PMLiVE

Teva wins challenge to BMS’ Baraclude patent in US

US court says hepatitis B treatment’s patent is invalid

- PMLiVE

BMS licenses OTC rights to Reckitt for $482m

Will market products including Picot, Tempra and Graneodin in Latin America

- PMLiVE

GSK signs obesity research deal with Vanderbilt University

Follows increased push from pharma to tackle the public health challenge

- PMLiVE

FDA turns down Novo Nordisk’s Tresiba and Ryzodeg

Decision could delay the US launch of the diabetes drugs by two years or more

EU flag

Five pharma companies begin antibiotic research programme

Sanofi, GSK and AstraZeneca among the collaborators on European projects

- PMLiVE

GSK planning restructuring in Europe as earnings fall

Includes job cuts and potential sale of Ribena/Lucozade brands

- PMLiVE

GSK signs up to AllTrials trial transparency campaign

Will publish formal clinical study reports for all of its medicines

- PMLiVE

GSK forms Indian vaccine research joint venture

Will work with local firm Biological E on six-in-one combination vaccine

- PMLiVE

GSK appoints Heineken and Shell director Hans Wijers to board

Is also chair designate of the brewery firm

Bristol-Myers Squibb (BMS) building

BMS Q4 results see earnings increase despite fall in sales

Cost-cutting measures at pharma company help overcome patent losses

- PMLiVE

NICE backs BMS-Pfizer’s Eliquis in atrial fibrillation

Final draft guidance recommends the drug for common heart condition

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links